首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1680749篇
  免费   124360篇
  国内免费   3676篇
耳鼻咽喉   21703篇
儿科学   55429篇
妇产科学   46033篇
基础医学   239300篇
口腔科学   48642篇
临床医学   149218篇
内科学   329519篇
皮肤病学   38607篇
神经病学   130121篇
特种医学   63717篇
外国民族医学   242篇
外科学   256227篇
综合类   38777篇
一般理论   531篇
预防医学   122929篇
眼科学   39941篇
药学   122979篇
  7篇
中国医学   4344篇
肿瘤学   100519篇
  2019年   13250篇
  2018年   19596篇
  2017年   15024篇
  2016年   16412篇
  2015年   18740篇
  2014年   26116篇
  2013年   37854篇
  2012年   52661篇
  2011年   55348篇
  2010年   32687篇
  2009年   30624篇
  2008年   51458篇
  2007年   54720篇
  2006年   55166篇
  2005年   52471篇
  2004年   50666篇
  2003年   48035篇
  2002年   46239篇
  2001年   91685篇
  2000年   93437篇
  1999年   76600篇
  1998年   18774篇
  1997年   16266篇
  1996年   16417篇
  1995年   16636篇
  1994年   15228篇
  1993年   14000篇
  1992年   57307篇
  1991年   55256篇
  1990年   52927篇
  1989年   50718篇
  1988年   46108篇
  1987年   44920篇
  1986年   42193篇
  1985年   39978篇
  1984年   29310篇
  1983年   24844篇
  1982年   13842篇
  1981年   12325篇
  1979年   25467篇
  1978年   17523篇
  1977年   14842篇
  1976年   13799篇
  1975年   14488篇
  1974年   17579篇
  1973年   16887篇
  1972年   15641篇
  1971年   14424篇
  1970年   13407篇
  1969年   12489篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Modified-release opioids are often prescribed for the management of moderate to severe acute pain following total hip and knee arthroplasty, despite recommendations against their use due to increasing concerns regarding harm. The primary objective of this multicentre study was to examine the impact of modified-release opioid use on the incidence of opioid-related adverse events compared with immediate-release opioid use, among adult inpatients following total hip or knee arthroplasty. Data for total hip and knee arthroplasty inpatients receiving an opioid analgesic for postoperative analgesia during hospitalisation were collected from electronic medical records of three tertiary metropolitan hospitals in Australia. The primary outcome was the incidence of opioid-related adverse events during hospital admission. Patients who received modified with or without immediate-release opioids were matched to those receiving immediate-release opioids only (1:1) using nearest neighbour propensity score matching with patient and clinical characteristics as covariates. This included total opioid dose received. In the matched cohorts, patients given modified-release opioids (n = 347) experienced a higher incidence of opioid-related adverse events overall, compared with those given immediate-release opioids only (20.5%, 71/347 vs. 12.7%, 44/347; difference in proportions 7.8% [95%CI 2.3–13.3%]). Modified-release opioid use was associated with an increased risk of harm when used for acute pain during hospitalisation after total hip or knee arthroplasty.  相似文献   
4.
5.
Pharmaceutical Research - The quality testing and approval procedure for most pharmaceutical products is a streamlined process with standardized procedures for the determination of critical quality...  相似文献   
6.
Renal cell cancer (RCC) represents 2%-3% of all adulthood cancers and is the most common malignant neoplasm of the kidney (90%). In the mid-nineties of the last century, the standard of treatment for patients with metastatic RCC was cytokines. Sunititib and pazopanib were registered in 2007 and 2009, respectively, and have since been the standard first-line treatment for metastatic clear cell RCC (mccRCC). Renal cell cancer is a highly immunogenic tumor with tumor infiltrating cells, including CD8+ T lymphocytes, dendritic cells, natural killer cells (NK) and macrophages. This observation led to the design of new clinical trials in which patients were treated with immunotherapy. With the growing evidence that proangiogenic factors can have immunomodulatory effects on the host’s immune system, the idea of combining angiogenic drugs with immunotherapy has emerged, and new clinical trials have been designed. In the last few years, several therapeutic options have been approved [immunotherapy and immunotherapy/tyrosine kinase inhibitors (TKI)] for the first-line treatment of mccRCC. Nivolumab/ipilimumab is approved for the treatment of patients with intermediate and poor prognoses. Several checkpoint inhibitors (pembrolizumab, nivolumab, avelumab) in combination with TKI (axitinib, lenvatinib, cabozantinib) are approved for the treatment of patients regardless of their International mRCC Database Consortium prognostic group and PD-L1 expression. There is no specific and ideal biomarker that could help in selecting the ideal patient for the appropriate first-line treatment.  相似文献   
7.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
8.
9.
10.
Journal of Pharmacokinetics and Pharmacodynamics - The integration between physiologically-based pharmacokinetics (PBPK) models and pharmacodynamics (PD) models makes it possible to describe the...  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号